Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
CLINSQUARE: CLINICAL RESEARCH COURSES
Wednesday, June 11, 2025
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Facebook
Twitter
CLINSQUARE: Clinical Rsearch Courses by LIFEPRONOW
Home
Pharma News
CDM
Clinical Research
Medical Writing
Regulatory Affairs
More
Clinical coding (Medical)
Clinical Research Associate
Centralized Monitoring
HEOR (Health Economics and Outcome Research)
Pharmacovigilance
Scientific Writing
Other
About us
Search
Home
Latest Pharma-News
Latest Pharma-News
Latest Pharma-News
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
admin
-
June 4, 2025
Latest Pharma-News
FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People
admin
-
June 4, 2025
Latest Pharma-News
J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin
admin
-
April 11, 2025
Latest Pharma-News
Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
admin
-
April 9, 2025
Latest Pharma-News
Novartis receives FDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
admin
-
April 9, 2025
Latest Pharma-News
Can an existing HIV medication slow the spread of COVID-19?
admin
-
April 29, 2020
0
Latest Pharma-News
Novartis announces plan to initiate clinical trial of canakinumab for patients with COVID-19 pneumonia
admin
-
April 29, 2020
0
Latest Pharma-News
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
admin
-
April 28, 2020
0
Latest Pharma-News
Sanofi and Regeneron provide an update on U.S. Phase 2/3 adaptive-designed trial of Kevzara® (sarilumab) in hospitalized COVID-19 patients
admin
-
April 28, 2020
0
Latest Pharma-News
Sanofi: Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in...
admin
-
April 28, 2020
0
Latest Pharma-News
Coronavirus (COVID-19) Update: FDA Continues to Ensure Availability of Alcohol-Based Hand Sanitizer During the COVID-19 Pandemic, Addresses Safety Concerns
admin
-
April 27, 2020
0
Latest Pharma-News
FDA Warns Manufacturers and Retailers to Remove Certain E-cigarette Products Targeted to Youth from the Market
admin
-
April 27, 2020
0
Latest Pharma-News
Novacyt contract with the UK Department of Health and Social Care for the supply of COVID-19 PCR tests
admin
-
April 27, 2020
0
Latest Pharma-News
FDA Warns of Heart Risks With Trump-Promoted Malaria Drug
admin
-
April 25, 2020
0
Latest Pharma-News
FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination
admin
-
April 25, 2020
0
Latest Pharma-News
Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19
admin
-
April 25, 2020
0
Latest Pharma-News
Scancell to initiate development of novel DNA vaccine against COVID-19
admin
-
April 25, 2020
0
1
...
118
119
120
...
145
Page 119 of 145
- Advertisment -
Most Read
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
June 4, 2025
FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People
June 4, 2025
J&J announced Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin
April 11, 2025
Sanofi’s Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
April 9, 2025